Introduction. The lack of effective aetiotropic therapy of COVID-19 prompted researchers around the world searching for various methods of SARS-CoV-2 elimination, including convalescent plasma. The aim of this work was to study the safety and efficacy of severe COVID-19 treatment with convalescence plasma containing specific antibodies to the receptor binding domain (RBD) of SARS-CoV-2 S protein in a titer of at least 1: 1000. Methods. A single-center, randomized, prospective, clinical study performed at the FRCC FMBA of Russia with the participation of 85 patients who were stratified in two groups. The first group contains 20 critically ill patients who are on mechanical ventilation; Results. The use of plasma of convalescents in patients with severe COVID-19 with mechanical ventilation does not affect the disease outcome in these patients. Mortality rate in this group was 60%, which corresponds to the average mortality of patients on mechanical ventilation in our hospital. In the second group clinical improvement was detected in 75% and 51%, for convalescent and normal plasma respectively. Of the 46 people who received convalescent plasma, three patients (6.5%) were transferred to mechanical ventilation, two of whom died. In the group receiving non-immune plasma, the need for mechanical ventilation also arose in three patients (15%), of which two died. The hospital mortality in the group of convalescent plasma was 4.3%, which is significantly lower than the average COVID-19 hospital mortality in our Center (6.73%) and more than two times lower than the hospital mortality in the control group (n = 150), matched by age and by the disease severity. Conclusions. Thus, we demonstrated relative safety of convalescent plasma transfusion and the effectiveness of such therapy for COVID-19 at least in terms of the survival of patients with severe respiratory failure without mechanical ventilation. In the absence of bioengineered neutralizing antibodies and effective aetiotropic therapy, the use of hyperimmune convalescent plasma is the simplest and most effective method of specific etiopathogenetic therapy using forms of COVID-19.

No abstract

treatment of patients with primary and recurrent locally advanced pelvic tumors represents an extremely complex problem of surgical oncology.Aim: to evaluate perioperative and long-term postoperative results of laparoscopic pelvic exenteration technique.Material and methods: in the period from 2011 to 2018, 21 pelvic exenteration was performed with laparoscopic access, (mean age 59.79 ± 8.5), sex distribution: 17 women and 4 men. Nosology distribution: in 6 patients cervical cancer was verified, 7 patients had bladder cancer, 4 patients had rectal cancer, 1 patient had vaginal cancer, 2 patients had recurrence of vaginal cancers after previous uterine extirpation and 1 patient with ovarian neoplasm.Results: the volume of the exenteration was as follows: 9 total, 7 anterior and 5 posterior. In all cases, it was possible to achieve a negative margin of resection line (R0). The duration of the operation, the volume of blood loss, the frequency and nature of intra- and postoperative complications were evaluated.Conclusion: laparoscopic access is accompanied by a smaller amount of blood loss, decrease of frequency of early postoperative complications, contributes to more comfortable postoperative period with early activation, less severe pain syndrome and leads to a reduction in the duration of inpatient treatment.

No abstract

No abstract